Brokers Offer Predictions for Antibe Therapeutics Inc.’s FY2024 Earnings (OTCMKTS:ATBPF)

Antibe Therapeutics Inc. (OTCMKTS:ATBPF) – Equities researchers at Echelon Wealth Partners boosted their FY2024 earnings per share (EPS) estimates for shares of Antibe Therapeutics in a report released on Monday, November 13th. Echelon Wealth Partners analyst S. Quenneville now anticipates that the company will post earnings of ($0.32) per share for the year, up from their previous forecast of ($0.35). The consensus estimate for Antibe Therapeutics’ current full-year earnings is ($0.31) per share.

Separately, Brookline Capital Management restated a “buy” rating on shares of Antibe Therapeutics in a report on Monday, August 14th.

Antibe Therapeutics Stock Performance

ATBPF opened at $0.55 on Thursday. Antibe Therapeutics has a 1 year low of $0.28 and a 1 year high of $0.89. The company’s 50 day simple moving average is $0.44 and its 200 day simple moving average is $0.40. The stock has a market capitalization of $28.90 million, a PE ratio of -2.20 and a beta of 0.27.

Antibe Therapeutics (OTCMKTS:ATBPF) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02.

Antibe Therapeutics Company Profile

Antibe Therapeutics Inc, a biotechnology company, engages in developing novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. The company's pipeline includes therapies that seek to overcome the gastrointestinal (GI) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs).